Яков Пеер

Должность: Офтальмолог, специалист в области онкологии
Языки: Иврит, Английский
Принимает: детей и взрослых


Профессор Яков Пеер - старший врач отделения офтальмологии.

Образование

Выпускник медицинского факультета Еврейского университета в Иерусалиме. Завершил ординатуру в области офтальмологии в 1985 году.

Специализация

Области клинической специализации:

  • Общая офтальмология
  • Онкология глаза
  • Патология глаза
  • Детская офтальмология
Академические интересы:
  • Онкологическая офтальмология
  • Пролиферация нормальных и патологических клеток
  • Васкулогенез и ангиогенез и нео-васкуляризация глазных тканей во внутриглазных новообразованиях.

Профессиональная деятельность

  • Заведующий отделением офтальмологии (до 2018 г.)
  • Заведующий кафедрой изучения глаза
  • Директор онко-офтальмологической службы
  • Заместитель декана по академическим вопросам факультет медицины Еврейского университета, Иерусалим
  • Председатель международной комиссии американской организации по изучению глаза
  • Член рекомендательной комиссии международного союза медицины глаз
  • С 2007-го года председатель международного общества онкологии глаза

Научные публикации

Treatment Outcomes and Definition Inconsistencies in High-Risk Unilateral Retinoblastoma
High-Risk Histopathological Features of Retinoblastoma following Primary Enucleation: A Global Study of 1426 Patients from 5 Continents
Treatment of conjunctival palpebral lesions using ruthenium plaque brachytherapy "Sandwich Technique"
The effect of systemic acetazolamide administration on intraocular pressure in healthy horses-A preliminary study
A retinoscopic survey of donkeys and goats
The challenge in the diagnosis and management of vitreoretinal lymphoma
sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma
Vitreoretinal lymphoma: Central nervous system lymphoma risk with unilateral or bilateral ocular tumour. A multicentre collaboration
Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma
Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience
Visual assessment of commercial drivers in the South West Region of Cameroon
VHL-Related Neuroendocrine Neoplasms And Beyond: An Israeli Specialized Center Real-Life Report
Naturally-occurring myopia and loss of cone function in a sheep model of achromatopsia
Global Retinoblastoma Presentation and Analysis by National Income Level
The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma
REDUCTION OF POSTINTRAVITREAL INJECTION PAIN USING ICE: An Open-Label Interventional Randomized Controlled Trial
The impact of monocular vision on motor function and quality of life in survivors of retinoblastoma
Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference
A novel combinatorial treatment option for metastatic uveal melanoma
Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
ADVANCES IN THE TREATMENT OF RETINOBLASTOMA AT HADASSAH IN THE LAST THREE DECADES
Centennial Anniversary of the Department of Ophthalmology of the Hadassah Medical Center, 1918-2018
Frequency, comprehension and attitudes of physicians towards abbreviations in the medical record
Leucine-Rich α-2-Glycoprotein-1 (LRG-1) Expression in Retinoblastoma
Long-term uveal melanoma survivors: measuring their quality of life
Peripapillary distribution of Muller cells within the retinal nerve fiber layer in human eyes
An international survey of classification and treatment choices for group D retinoblastoma
Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma
Pathology of eyelid tumors
Genotype-phenotype correlation in the presentation of retinoblastoma among 149 patients
Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome
The Pediatric Choroidal and Ciliary Body Melanoma Study: A Survey by the European Ophthalmic Oncology Group
Whole Exome Sequencing Reveals Mutations in Known Retinal Disease Genes in 33 out of 68 Israeli Families with Inherited Retinopathies
Genetic screening in patients with Retinoblastoma in Israel
Authors' response: Pars planavitrectomy to repair retinal detachment following brachytherapy for uveal melanoma
Paediatric and adolescent elevated conjunctival lesions in the plical area: lymphoma or reactive lymphoid hyperplasia?
Pars plana vitrectomy to repair retinal detachment following brachytherapy for uveal melanoma
PfSec13 is an unusual chromatin-associated nucleoporin of Plasmodium falciparum that is essential for parasite proliferation in human erythrocytes
Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans
Gender differences in clinical presentation and prognosis of uveal melanoma
Choroidal metastasis of adenocarcinoma of the lung presenting as pigmented choroidal tumor
Ruthenium-106 brachytherapy
Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers
Participation in daily activities and quality of life in survivors of retinoblastoma
VEGF as a biomarker for metastatic uveal melanoma in humans
Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2)
The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1)
Calcification in retinoblastoma: histopathologic findings and statistical analysis of 302 cases
Homozygosity mapping reveals null mutations in FAM161A as a cause of autosomal-recessive retinitis pigmentosa
Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity
Показать ещё 42 статьи Скрыть статьи
Заболевания
Ретинобластома
Увеальная меланома
Медуллоэпителиома
Опухоли век
Халязион
Интраокулярная лимфома
Пиломатриксома
Хориоидальная гемангиома
Процедуры
Интраартериальная химиотерапия
Брахитерапия
Остались вопросы?
Напишите нам и мы свяжемся с вами в течение ближайшего времени и ответим на все интересующие вопросы